Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders

Zhaohui Ye, Huichun Zhan, Prashant Mali, Sarah Dowey, Donna M. Williams, Yoon Young Jang, Chi V. Dang, Jerry L Spivak, Alison R Moliterno, Linzhao Cheng

Research output: Contribution to journalArticle

Abstract

Human induced pluripotent stem (iPS) cells derived from somatic cells hold promise to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. We and others previously reprogrammed human adherent cells, such as postnatal fibroblasts to iPS cells, which resemble adherent embryonic stem cells. Here we report derivation of iPS cells from postnatal human blood cells and the potential of these pluripotent cells for disease modeling. MultiplehumaniPS cell lines were generated from previously frozen cord blood or adult CD34+ cells of healthy donors, and could be redirected to hematopoietic differentiation. Multiple iPS cell lines were also generated from peripheral blood CD34+ cells of 2 patients with myeloproliferative disorders (MPDs) who acquired the JAK2-V617F somatic mutation in their blood cells. The MPD-derived iPS cells containing the mutation appeared normal in phenotypes, karyotype, and pluripotency. After directed hematopoietic differentiation, the MPD-iPS cell-derived hematopoietic progenitor (CD34+CD45+) cells showed the increased erythropoiesis and gene expression of specific genes, recapitulating features of the primary CD34+ cells of the corresponding patient from whom the iPS cells were derived. These iPS cells provide a renewable cell source and a prospective hematopoiesis model for investigating MPD pathogenesis.

Original languageEnglish (US)
Pages (from-to)5473-5480
Number of pages8
JournalBlood
Volume114
Issue number27
DOIs
StatePublished - Dec 24 2009

Fingerprint

Induced Pluripotent Stem Cells
Stem cells
Blood Cells
Blood
Cells
Tissue Donors
Myeloproliferative Disorders
Cell Line
Mutation
Erythropoiesis
Hematopoiesis
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Fetal Blood
Karyotype
Fibroblasts
Gene expression
Genes
Phenotype
Gene Expression

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. / Ye, Zhaohui; Zhan, Huichun; Mali, Prashant; Dowey, Sarah; Williams, Donna M.; Jang, Yoon Young; Dang, Chi V.; Spivak, Jerry L; Moliterno, Alison R; Cheng, Linzhao.

In: Blood, Vol. 114, No. 27, 24.12.2009, p. 5473-5480.

Research output: Contribution to journalArticle

Ye, Zhaohui ; Zhan, Huichun ; Mali, Prashant ; Dowey, Sarah ; Williams, Donna M. ; Jang, Yoon Young ; Dang, Chi V. ; Spivak, Jerry L ; Moliterno, Alison R ; Cheng, Linzhao. / Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. In: Blood. 2009 ; Vol. 114, No. 27. pp. 5473-5480.
@article{3b5c3a4af98b4e508543d02220aabca4,
title = "Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders",
abstract = "Human induced pluripotent stem (iPS) cells derived from somatic cells hold promise to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. We and others previously reprogrammed human adherent cells, such as postnatal fibroblasts to iPS cells, which resemble adherent embryonic stem cells. Here we report derivation of iPS cells from postnatal human blood cells and the potential of these pluripotent cells for disease modeling. MultiplehumaniPS cell lines were generated from previously frozen cord blood or adult CD34+ cells of healthy donors, and could be redirected to hematopoietic differentiation. Multiple iPS cell lines were also generated from peripheral blood CD34+ cells of 2 patients with myeloproliferative disorders (MPDs) who acquired the JAK2-V617F somatic mutation in their blood cells. The MPD-derived iPS cells containing the mutation appeared normal in phenotypes, karyotype, and pluripotency. After directed hematopoietic differentiation, the MPD-iPS cell-derived hematopoietic progenitor (CD34+CD45+) cells showed the increased erythropoiesis and gene expression of specific genes, recapitulating features of the primary CD34+ cells of the corresponding patient from whom the iPS cells were derived. These iPS cells provide a renewable cell source and a prospective hematopoiesis model for investigating MPD pathogenesis.",
author = "Zhaohui Ye and Huichun Zhan and Prashant Mali and Sarah Dowey and Williams, {Donna M.} and Jang, {Yoon Young} and Dang, {Chi V.} and Spivak, {Jerry L} and Moliterno, {Alison R} and Linzhao Cheng",
year = "2009",
month = "12",
day = "24",
doi = "10.1182/blood-2009-04-217406",
language = "English (US)",
volume = "114",
pages = "5473--5480",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "27",

}

TY - JOUR

T1 - Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders

AU - Ye, Zhaohui

AU - Zhan, Huichun

AU - Mali, Prashant

AU - Dowey, Sarah

AU - Williams, Donna M.

AU - Jang, Yoon Young

AU - Dang, Chi V.

AU - Spivak, Jerry L

AU - Moliterno, Alison R

AU - Cheng, Linzhao

PY - 2009/12/24

Y1 - 2009/12/24

N2 - Human induced pluripotent stem (iPS) cells derived from somatic cells hold promise to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. We and others previously reprogrammed human adherent cells, such as postnatal fibroblasts to iPS cells, which resemble adherent embryonic stem cells. Here we report derivation of iPS cells from postnatal human blood cells and the potential of these pluripotent cells for disease modeling. MultiplehumaniPS cell lines were generated from previously frozen cord blood or adult CD34+ cells of healthy donors, and could be redirected to hematopoietic differentiation. Multiple iPS cell lines were also generated from peripheral blood CD34+ cells of 2 patients with myeloproliferative disorders (MPDs) who acquired the JAK2-V617F somatic mutation in their blood cells. The MPD-derived iPS cells containing the mutation appeared normal in phenotypes, karyotype, and pluripotency. After directed hematopoietic differentiation, the MPD-iPS cell-derived hematopoietic progenitor (CD34+CD45+) cells showed the increased erythropoiesis and gene expression of specific genes, recapitulating features of the primary CD34+ cells of the corresponding patient from whom the iPS cells were derived. These iPS cells provide a renewable cell source and a prospective hematopoiesis model for investigating MPD pathogenesis.

AB - Human induced pluripotent stem (iPS) cells derived from somatic cells hold promise to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. We and others previously reprogrammed human adherent cells, such as postnatal fibroblasts to iPS cells, which resemble adherent embryonic stem cells. Here we report derivation of iPS cells from postnatal human blood cells and the potential of these pluripotent cells for disease modeling. MultiplehumaniPS cell lines were generated from previously frozen cord blood or adult CD34+ cells of healthy donors, and could be redirected to hematopoietic differentiation. Multiple iPS cell lines were also generated from peripheral blood CD34+ cells of 2 patients with myeloproliferative disorders (MPDs) who acquired the JAK2-V617F somatic mutation in their blood cells. The MPD-derived iPS cells containing the mutation appeared normal in phenotypes, karyotype, and pluripotency. After directed hematopoietic differentiation, the MPD-iPS cell-derived hematopoietic progenitor (CD34+CD45+) cells showed the increased erythropoiesis and gene expression of specific genes, recapitulating features of the primary CD34+ cells of the corresponding patient from whom the iPS cells were derived. These iPS cells provide a renewable cell source and a prospective hematopoiesis model for investigating MPD pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=70450247528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450247528&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-04-217406

DO - 10.1182/blood-2009-04-217406

M3 - Article

C2 - 19797525

AN - SCOPUS:70450247528

VL - 114

SP - 5473

EP - 5480

JO - Blood

JF - Blood

SN - 0006-4971

IS - 27

ER -